The SEC has received an amended S-1/A registration statement for the 21Shares Injective ETF. This filing updates the original proposal submitted on October 20, 2025, and aims to provide traditional investors with regulated access to the INJ token, which is the native asset of the Injective Network.
If approved, the fund will be listed on Nasdaq under the ticker symbol TINJ. The ETF is structured as a Delaware statutory trust and is sponsored by 21Shares US LLC. The investment strategy focuses on tracking the performance of INJ tokens through the FTSE Injective Index.
A key feature of the proposed fund is the discretionary staking of a portion of its holdings to potentially increase returns. In 2025, annual staking rewards for INJ ranged between 9.3% and 13.62%. As of September 1, 2026, the circulating supply of INJ was 92.8 million tokens.
The market capitalization of the INJ token was approximately $488 million as of September 1, 2026. While the registration process continues, the filing notes that custody arrangements for the assets remain unfinalized. No financial statements are included at this stage.
